Peptide Therapy: 17 Peptides, 4 Clinical Categories, and How to Choose the Right Protocol
Table of Contents
- What Peptide Therapy Is
- How Peptides Work: The Cell Receptor Signaling Mechanism
- The 4 Clinical Categories of Peptide Therapy
- Category 1: Healing and Repair Peptides (BPC-157, TB-500, KPV)
- Category 2: Hormonal Optimization Peptides (CJC-1295, Ipamorelin, Tesamorelin)
- Category 3: Cognitive and Neurological Peptides (Semax, Selank, Epithalon, Thymalin)
- Category 4: Metabolic and Weight Management Peptides (Semaglutide, Tirzepatide)
- Stacking Concepts: Combining Peptides for Synergistic Results
- Who Is a Candidate for Peptide Therapy
- The Consultation Process: Labs, Goals, and Protocol Design
- Results and Realistic Expectations
- Costs and What the Protocol Includes
- How Do You Know Which Peptide Protocol Is Right for Your Goals?
- Frequently Asked Questions
- When Peptide Therapy Is Not Indicated
What Peptide Therapy Is
Peptide therapy is a medical intervention that uses short chains of amino acids, synthetic or bioidentical, to trigger specific biological responses including tissue repair, hormone secretion, immune modulation, and metabolic regulation.
The word "peptide" describes a molecule made of two or more amino acids linked by peptide bonds. In biological terms, peptides are signaling molecules. The body uses endogenous peptides to communicate between cells, trigger enzymatic activity, regulate hormone release, and coordinate repair processes. When the body's natural peptide production is insufficient or when a specific biological response needs to be amplified, exogenous peptide administration delivers the signal that the body's own production cannot adequately supply.
Peptide therapy at Rebuild Regen Medical Clinic is a physician-managed service. Elizabeth Celestin, APRN, FNP-C, designs peptide protocols based on comprehensive lab evaluation and patient goals. No peptide protocol is initiated without a clinical consultation and appropriate baseline testing. The specificity of peptide therapy, each peptide triggers a discrete biological pathway rather than producing broad non-specific effects, is what makes it clinically precise when used under appropriate oversight.
This guide covers 17 peptides across four clinical categories, the mechanisms behind each, how they are combined into effective protocols, and what to expect from treatment.
How Peptides Work: The Cell Receptor Signaling Mechanism
Peptide therapy works by delivering specific amino acid sequences that bind to cell surface receptors, triggering intracellular signaling cascades that produce the desired physiological response.
Each peptide is structurally specific. The sequence of amino acids determines which receptor it binds to and what downstream effect it produces. This is the opposite of broad-spectrum pharmacology. A peptide like BPC-157 binds to growth hormone receptors and cytokine receptors in tissue, initiating repair signaling. A peptide like CJC-1295 binds to growth hormone releasing hormone (GHRH) receptors on the pituitary, triggering a pulse of growth hormone secretion. The specificity is built into the molecular structure.
Why short half-lives matter: Many peptides have short biological half-lives, meaning they are degraded relatively quickly in the body. This is actually a safety feature: the effect is driven by the receptor interaction, not by sustained presence. Some peptides have been modified to extend their half-life (CJC-1295 with DAC is a modified analog designed to bind to albumin and extend activity), while others are designed to work in short pulses that mimic natural physiological signaling (Ipamorelin, which produces a growth hormone pulse similar to natural secretion).
Bioidentical vs. synthetic peptides: Some therapeutic peptides are synthetic analogs of endogenous molecules. BPC-157 is a synthetic peptide derived from body protection compound found naturally in gastric juice. Ipamorelin is a synthetic ghrelin receptor agonist. Semaglutide is a synthetic GLP-1 receptor agonist. Others, like Epithalon, are synthetic peptides based on sequences not produced endogenously at therapeutic levels. The distinction affects regulatory classification and research context.
Administration: Most peptides are administered via subcutaneous injection (the most reliable delivery method ensuring consistent absorption), though some can be delivered orally, topically, or intranasally depending on their molecular characteristics and the clinical application.
The 4 Clinical Categories of Peptide Therapy
Peptide therapy at Rebuild Regen is organized into four clinical categories, each addressing a different physiological domain. Most patients present with goals in one or two categories; some have goals spanning all four.
- Healing and Repair: BPC-157, TB-500, KPV
- Hormonal Optimization: CJC-1295, Ipamorelin, Tesamorelin
- Cognitive and Neurological: Semax, Selank, Epithalon, Thymalin
- Metabolic and Weight Management: Semaglutide, Tirzepatide
The additional peptides covered include PT-141 (sexual function), Melanotan II (pigmentation and sexual function), LL-37 (antimicrobial/immune), Thymosin Alpha-1 (immune modulation), and Cerebrolysin (cognitive/neuroprotective), bringing the clinic's active peptide formulary to 17.
Category 1: Healing and Repair Peptides
Healing and repair peptides accelerate tissue recovery, reduce localized inflammation, and support regeneration of tendon, muscle, ligament, gut, and nerve tissue. This category sees the highest demand from athletes, post-surgical patients, and individuals with chronic injury or inflammatory conditions.
BPC-157 (Body Protection Compound 157)
BPC-157 is a synthetic pentadecapeptide derived from a sequence found in gastric juice that exerts potent tissue repair, anti-inflammatory, and cytoprotective effects across musculoskeletal, gastrointestinal, and neurological tissue.
BPC-157 is one of the most extensively studied peptides in regenerative medicine. Its primary mechanisms include:
- Upregulation of growth hormone receptors in tendon fibroblasts, directly accelerating tendon and ligament healing
- Stimulation of VEGF (vascular endothelial growth factor) to increase blood vessel formation at injury sites
- Modulation of NO (nitric oxide) pathways that reduce localized inflammation
- Gut epithelium cytoprotection, making it the primary peptide for inflammatory bowel disease support, leaky gut, and gastric ulcer healing
- Neuroprotective effects on peripheral and central nervous system tissue
Clinical applications at Rebuild Regen:
- Tendon and ligament injuries (rotator cuff, Achilles, patellar, ACL recovery)
- Inflammatory bowel disease, leaky gut, GERD-related mucosal damage
- Muscle tears and chronic muscle soreness in athletes
- Post-surgical healing acceleration
- Neuropathy support (combined with other Rebuild Neuropathy Protocol modalities)
Administration: Subcutaneous injection at or near the injury site (localized) or systemic subcutaneous injection. Some patients tolerate oral BPC-157 for gut-specific applications, though systemic absorption via oral route is less predictable.
Dose range: 200 to 500 mcg per injection, once or twice daily depending on the protocol.
TB-500 (Thymosin Beta-4 Fragment)
TB-500 is a synthetic fragment of Thymosin Beta-4, an endogenous peptide involved in actin regulation, cell migration, angiogenesis, and wound healing that promotes tissue repair across multiple tissue types simultaneously.
Thymosin Beta-4 is present in high concentrations in platelets and is released at injury sites as part of the natural healing response. TB-500 provides a concentrated synthetic analog of its active fragment.
Mechanisms:
- Promotes cell migration to injury sites (critical for tissue repair initiation)
- Upregulates actin polymerization, which drives cell mobility and tissue remodeling
- Stimulates angiogenesis (new blood vessel formation) at repair sites
- Anti-inflammatory via downregulation of NF-kB and reduction in pro-inflammatory cytokines
TB-500 vs. BPC-157: These two peptides are frequently stacked. BPC-157 is particularly powerful for tendon, ligament, and gut applications. TB-500 is more broadly systemic and effective for large muscle injuries, cardiac tissue, and widespread inflammatory conditions. Together, they cover the full tissue repair spectrum.
Clinical applications:
- Large muscle injuries (hamstring, quadriceps, calf)
- Cardiac tissue support (some evidence for benefit post-myocardial injury)
- Systemic anti-inflammatory burden reduction
- Athletes with multiple concurrent injury sites
Administration: Subcutaneous injection. Typical dose 2 to 5 mg per injection, 2 to 3 times per week during the acute phase, transitioning to once weekly for maintenance.
KPV (Lys-Pro-Val)
KPV is a tripeptide fragment of the alpha-melanocyte stimulating hormone (alpha-MSH) that functions as a potent anti-inflammatory agent, particularly in gastrointestinal tissue and skin, with immune-modulating properties.
KPV targets the melanocortin receptors (MC1R and MC3R) that mediate the anti-inflammatory action of alpha-MSH. By activating these receptors, KPV reduces NF-kB activation, decreases production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-8), and reduces inflammatory damage to epithelial tissue.
Clinical applications:
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis) as a symptom modifier
- Skin inflammatory conditions (psoriasis, atopic dermatitis, wound healing)
- Post-radiation gut damage in cancer treatment recovery
- Gut inflammation adjunct alongside BPC-157 for comprehensive gut repair protocols
Administration: Oral capsule for gut-specific applications (resistant to GI degradation unlike many other peptides); subcutaneous for systemic anti-inflammatory use; topical preparation for skin conditions.
Category 2: Hormonal Optimization Peptides
Hormonal optimization peptides stimulate the body's own hormone-producing systems, primarily the growth hormone axis, to restore more youthful levels of growth hormone (GH) and IGF-1 without directly replacing hormones with exogenous compounds.
This distinction is clinically significant. These peptides trigger the pituitary to release growth hormone in natural pulses, maintaining the physiological feedback loop, rather than introducing synthetic growth hormone that bypasses regulation.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary to release growth hormone. It is available in two forms: CJC-1295 without DAC (shorter acting, peak and decay), and CJC-1295 with DAC (Drug Affinity Complex), which binds to albumin and extends the half-life to several days.
Without DAC: produces a growth hormone pulse similar to natural GHRH stimulation. Used in combination with Ipamorelin for a synergistic, pulse-based growth hormone release.
With DAC: provides a sustained low-level growth hormone elevation over 7 to 10 days per injection. Used when consistent growth hormone support is desired over a longer window, though the blunted pulse pattern is less physiologically mimetic.
Mechanisms:
- Binds GHRH receptors on pituitary somatotrophs
- Stimulates growth hormone synthesis and release
- Increases downstream IGF-1 (insulin-like growth factor 1) production by the liver
- Promotes fat metabolism (lipolysis), muscle protein synthesis, and tissue repair
Clinical applications:
- Body composition optimization (muscle gain, fat reduction)
- Recovery acceleration in athletes
- Anti-aging longevity protocols
- Bone density support
- Combined with TRT for synergistic anabolic and recovery benefits
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist that stimulates pituitary growth hormone release with high selectivity and minimal side effects.
Ipamorelin's primary clinical advantage is specificity. Unlike older GH secretagogues (GHRP-2, GHRP-6), Ipamorelin does not significantly stimulate cortisol or prolactin release, and produces minimal appetite stimulation. This selectivity profile makes it the preferred GHS for most patients, particularly those sensitive to cortisol elevation or unwanted appetite effects.
CJC-1295 plus Ipamorelin stacking: This is the most common combination protocol in growth hormone optimization. CJC-1295 extends the GHRH signal; Ipamorelin provides the additional GHS stimulus. Together, they produce growth hormone pulses that are 3 to 5 times larger than Ipamorelin alone without significantly increasing cortisol or prolactin. The combination is typically injected at night before sleep, timing the pulse to the natural nocturnal growth hormone surge.
Clinical applications:
- Body composition optimization (primary GH peptide stack for most patients)
- Recovery and tissue repair support
- Sleep quality improvement (growth hormone promotes slow-wave sleep)
- Anti-aging protocols focusing on lean mass and fat metabolism
Administration: Subcutaneous injection, typically 100 to 300 mcg of each peptide per injection, once daily at bedtime.
Tesamorelin
Tesamorelin is a synthetic GHRH analog with FDA approval for HIV-associated lipodystrophy that reduces visceral fat via growth hormone axis stimulation.
Tesamorelin is the most clinically validated of the GHRH analogs, with FDA approval giving it a unique regulatory status among peptides. For non-HIV patients, tesamorelin is used off-label for visceral fat reduction and body composition improvement in patients where central adiposity is a primary concern.
Its mechanism is similar to CJC-1295 but with a different structural modification that produces a more consistent GHRH receptor stimulation profile. Studies in non-HIV patients show significant reductions in visceral adipose tissue (VAT) over 12 to 26 weeks.
Clinical applications:
- Visceral fat reduction (particularly central/abdominal adiposity)
- Metabolic syndrome component targeting
- Lipid profile improvement
- Combined with metabolic peptides (semaglutide or tirzepatide) for comprehensive body composition protocols
Category 3: Cognitive and Neurological Peptides
Cognitive and neurological peptides modulate neurotransmitter systems, reduce neuroinflammation, support nerve regeneration, and in some cases influence the aging-related processes of telomere biology and immune senescence.
Semax
Semax is a synthetic heptapeptide analog of ACTH (adrenocorticotropic hormone) that enhances cognitive function, neuroprotection, and neurotrophic factor expression in the central nervous system.
Semax was developed in Russia, where it has been used clinically for stroke recovery and cognitive enhancement for decades. Its primary mechanisms include:
- Upregulation of BDNF (brain-derived neurotrophic factor), the primary growth factor for neuron health and synaptogenesis
- Modulation of dopaminergic and serotonergic systems
- Anti-inflammatory effects in neural tissue
- Improved attention, focus, and working memory
Clinical applications:
- Cognitive enhancement in age-related cognitive decline
- Post-stroke or post-TBI neurological rehabilitation
- ADHD symptom management adjunct
- Anxiety and stress-related cognitive impairment
Administration: Intranasal spray (most common for cognitive applications); subcutaneous injection for higher doses. Typical dose 0.1 to 0.3 mg per application, once or twice daily.
Selank
Selank is a synthetic heptapeptide analog of the human immunoglobulin IgG that functions as an anxiolytic, nootropic, and immune-modulating peptide without dependence risk or sedation.
Selank was developed in parallel with Semax in Russian clinical research. Its primary distinction is the anxiolytic and anti-anxiety mechanism alongside cognitive enhancement, without the sedative profile of benzodiazepines or the dependence risk of pharmaceutical anxiolytics.
Mechanisms:
- Modulates GABA receptor sensitivity (anxiolytic mechanism)
- Inhibits enkephalin breakdown, extending the calming effect of endogenous opioids
- Enhances BDNF expression
- Immune modulating via IgG-derived action
Clinical applications:
- Generalized anxiety and stress-related cognitive impairment
- Combined with Semax for broad cognitive plus anxiolytic protocols
- Social anxiety in performance-sensitive contexts
- Neuroinflammatory conditions with anxiety component
Epithalon
Epithalon is a synthetic tetrapeptide that activates telomerase, extends telomere length in aging cells, and modulates the pineal gland to support circadian rhythm and age-related physiological decline.
Epithalon is the most longevity-focused peptide in this category. Its primary mechanism, telomerase activation, directly addresses one of the core biological processes of cellular aging. Telomeres shorten with each cell division, eventually triggering senescence. Epithalon stimulates telomerase to restore telomere length, potentially extending the replicative lifespan of affected cells.
Additional mechanisms:
- Stimulates pineal gland melatonin production (supports sleep quality and circadian function)
- Antioxidant activity reducing oxidative stress in aging tissue
- Immune modulation supporting thymus function
Clinical applications:
- Longevity and anti-aging protocols
- Circadian rhythm and sleep quality optimization
- Combination with Thymalin for comprehensive immune-aging protocols
- Post-cancer recovery to support cellular resilience
Typical protocol: Episodic (10 to 20 day cycles twice yearly rather than continuous daily use), subcutaneous injection.
Thymalin
Thymalin is a synthetic peptide of thymus origin that stimulates immune system activity, supports T-lymphocyte maturation, and counteracts the immune senescence associated with thymus involution in aging.
The thymus gland shrinks significantly after puberty, reducing T-cell output and contributing to the immune decline of aging (immunosenescence). Thymalin provides exogenous thymic peptide signaling to restore aspects of immune function that decline with thymus involution.
Clinical applications:
- Age-related immune decline and recurrent infections
- Post-infectious immune restoration
- Combined with Epithalon in longevity-focused immune protocols
- Autoimmune modulation support (reduced immune overactivation in some contexts)
Category 4: Metabolic and Weight Management Peptides
Metabolic peptides regulate insulin signaling, appetite, glucose metabolism, and fat oxidation. Two FDA-approved GLP-1 receptor agonists, semaglutide and tirzepatide, are the most clinically validated agents in this category and represent the evidence standard for pharmacological weight management.
Semaglutide
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that reduces appetite, slows gastric emptying, and improves insulin secretion and glucose regulation, producing significant weight loss and metabolic improvement in overweight and obese patients.
Semaglutide (brand names Ozempic for diabetes, Wegovy for weight loss) has transformed metabolic medicine. The STEP trial program demonstrated average weight loss of 14 to 17 percent of body weight over 68 weeks on semaglutide versus 2 percent for placebo. The SURMOUNT trial for tirzepatide showed even higher weight loss rates.
Mechanisms:
- GLP-1 receptor agonism reduces appetite via central hypothalamic signaling (reduces hunger signals, increases satiety signals)
- Slows gastric emptying, extending the sensation of fullness
- Stimulates insulin secretion in a glucose-dependent manner (only active when glucose is elevated, reducing hypoglycemia risk)
- Reduces glucagon secretion
- Directly reduces fatty liver deposition
Clinical applications at Rebuild Regen:
- Weight management for patients with BMI above 27 with comorbidities or BMI above 30
- Type 2 diabetes management adjunct
- Metabolic syndrome (combined with hormonal correction when indicated)
- Pre-surgical weight loss preparation
- Combined with Tesamorelin for visceral fat targeting protocols
Administration: Weekly subcutaneous injection. Starting dose 0.25 mg weekly, titrated slowly over 4 to 12 weeks to the therapeutic maintenance dose (up to 2.4 mg weekly for weight loss indication). Slow titration is the key to managing GI side effects.
Tirzepatide
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist that produces greater weight loss and metabolic improvement than semaglutide alone by targeting two incretin hormone pathways simultaneously.
Tirzepatide (brand name Mounjaro for T2D, Zepbound for weight loss) represents the current evidence leader in pharmacological weight management. The SURMOUNT-1 trial showed average weight loss of 20.9 percent at the highest dose over 72 weeks, nearly double the average weight loss seen with older GLP-1 agonists.
The dual mechanism of tirzepatide explains its superior efficacy: GIP receptor agonism adds effects on fat tissue (directly reducing adipocyte lipogenesis) and on beta cell function that GLP-1 agonism alone does not fully capture.
Clinical applications:
- Advanced weight management for patients with higher weight loss goals
- Type 2 diabetes with weight management as a co-primary goal
- Patients who have not achieved sufficient response on semaglutide
- Combined with body composition peptides (CJC-1295/Ipamorelin) for comprehensive body recomposition protocols
Administration: Weekly subcutaneous injection. Starting dose 2.5 mg weekly, titrated to therapeutic dose (up to 15 mg weekly) over 12 to 20 weeks. Side effect profile is similar to semaglutide.
Stacking Concepts: Combining Peptides for Synergistic Results
Peptide stacking refers to the deliberate combination of peptides that address complementary pathways, producing outcomes that neither peptide achieves alone. This is one of the most clinically sophisticated aspects of peptide therapy.
The Classic Body Composition Stack: CJC-1295 + Ipamorelin
The most widely used peptide stack. CJC-1295 extends the GHRH signal while Ipamorelin provides the additional GHS stimulus at the pituitary level. The combination produces growth hormone pulses 3 to 5 times larger than either alone. Administered at bedtime to amplify the natural nocturnal GH pulse. Effect: improved body composition, fat reduction, lean muscle support, better sleep, and enhanced tissue recovery.
The Injury Repair Stack: BPC-157 + TB-500
These two repair peptides cover complementary aspects of the healing cascade. BPC-157 is powerful at the local tendon, ligament, and gut level. TB-500 addresses broader muscle, cardiac, and systemic anti-inflammatory needs. Combined, they address acute injury from multiple repair angles simultaneously. Commonly used in athletes post-injury or post-surgery.
The Cognitive Performance Stack: Semax + Selank
Semax provides the nootropic and BDNF-stimulating effects. Selank adds the anxiolytic and calming component, reducing the cortisol-driven cognitive interference that accompanies stress. Together, they produce a focused, calm, high-performance cognitive state. Used by professionals in high-demand environments, executives, and patients with anxiety-related cognitive impairment.
The Longevity Stack: Epithalon + Thymalin
Epithalon addresses cellular aging via telomerase activation. Thymalin addresses immune senescence via thymic peptide restoration. Combined in episodic protocols (10 to 20 day cycles twice yearly), this stack targets two of the primary biological aging mechanisms simultaneously. Used in anti-aging longevity programs alongside growth hormone optimization and hormonal correction.
The Metabolic and Body Recomposition Stack: Tirzepatide + CJC-1295/Ipamorelin + Tesamorelin
For patients with significant weight loss goals combined with body composition optimization, this three-way protocol addresses appetite and insulin signaling (tirzepatide), growth hormone axis support for lean muscle preservation during caloric restriction (CJC/Ipamorelin), and targeted visceral fat reduction (tesamorelin). This is an advanced protocol designed at consultation after comprehensive metabolic and hormonal assessment.
Who Is a Candidate for Peptide Therapy
Peptide therapy is applicable to a wide range of patients with specific, identifiable goals.
Strong candidates include:
- Athletes with acute or chronic musculoskeletal injuries seeking repair support
- Patients with inflammatory bowel disease or chronic gut inflammation
- Men and women pursuing body composition optimization alongside or instead of TRT/HRT
- Patients with cognitive decline, focus, and memory concerns
- Patients with anxiety that has not responded adequately to lifestyle modification
- Individuals pursuing longevity optimization protocols
- Patients with type 2 diabetes or metabolic syndrome needing weight and glucose management
- Post-surgical patients seeking recovery acceleration
Patients for whom other interventions are the primary recommendation:
- Patients with specific structural deficits requiring mechanical correction (surgery, decompression) who need those addressed before repair peptides are clinically relevant
- Patients with active cancer requiring oncology clearance before growth-promoting peptides are initiated
- Patients with uncontrolled thyroid disease or unmanaged diabetes where the primary condition must be addressed first
The Consultation Process: Labs, Goals, and Protocol Design
No peptide protocol at Rebuild Regen is initiated without a consultation. The consultation serves three functions: understanding the patient's specific goals, establishing the lab baseline, and designing a protocol that addresses those goals through the most appropriate peptides and combination approach.
Labs for peptide therapy evaluation:
- Comprehensive metabolic panel (CMP)
- CBC with differential
- IGF-1 (baseline for growth hormone axis evaluation before GHRH peptides)
- Hormonal panel (testosterone, estradiol, thyroid) to identify concurrent hormonal issues that interact with peptide goals
- Fasting glucose and HbA1c for metabolic peptide candidates
- Lipid panel
Protocol design:
- Goal prioritization: repair, performance, cognition, metabolic, longevity — one to two primary goals per initial protocol
- Peptide selection from the appropriate category(ies)
- Stack design if multi-goal
- Administration schedule (timing, frequency, subcutaneous injection instruction)
- Duration and reassessment plan
Results and Realistic Expectations
Peptide therapy produces results on timelines that vary significantly by the peptide category and the specific goal.
Repair peptides (BPC-157, TB-500):
- Initial reduction in local inflammation: 1 to 2 weeks
- Measurable improvement in injury symptoms: 3 to 6 weeks
- Full tissue repair support: 8 to 16 weeks depending on injury severity
Growth hormone peptides (CJC-1295/Ipamorelin):
- Sleep quality improvements: 2 to 4 weeks
- Body composition changes (early): 4 to 8 weeks
- Significant fat loss and muscle changes: 3 to 6 months of consistent use
Cognitive peptides (Semax, Selank):
- Acute cognitive and anxiety effects: days to 1 to 2 weeks
- Sustained neurological changes: 4 to 8 weeks of consistent use
Metabolic peptides (Semaglutide, Tirzepatide):
- Appetite reduction: within 1 to 2 weeks of therapeutic dose
- Measurable weight loss: 4 to 8 weeks
- Significant weight reduction (10+ percent): 3 to 6 months at therapeutic dose
Costs and What the Protocol Includes
Peptide therapy pricing at Rebuild Regen depends on which peptides are prescribed, the protocol duration, and whether the protocol is standalone or combined with other treatments.
General pricing structure:
- Repair peptide protocols (BPC-157, TB-500, KPV): priced per protocol cycle
- Growth hormone optimization (CJC/Ipamorelin stacks): monthly subscription-style pricing
- Cognitive peptides: per protocol cycle
- Metabolic peptides (semaglutide, tirzepatide): monthly dosing cost plus monitoring
Exact pricing is provided at consultation. All pricing is transparent before any protocol begins.
Included:
- Elizabeth Celestin consultation and lab review
- Protocol design
- Injection training (for self-administered subcutaneous protocols)
- Follow-up at 4 to 6 weeks and 3 months
How Do You Know Which Peptide Protocol Is Right for Your Goals?
The peptide consultation answers this question by mapping the patient's specific goals to the peptide categories that address the underlying biology.
For injury recovery: BPC-157 for tendon, ligament, and gut applications; TB-500 for muscle and systemic; BPC-157 plus TB-500 for comprehensive injury repair.
For body composition: CJC-1295 plus Ipamorelin as the growth hormone stack foundation; Tesamorelin if visceral fat is the primary target; semaglutide or tirzepatide if weight loss is the primary metric and appetite/insulin management is the mechanism.
For cognitive performance and anxiety: Semax for pure cognitive enhancement; Selank for anxiety with cognitive support; Semax plus Selank for the combined profile.
For longevity: Epithalon plus Thymalin in episodic cycles; combined with growth hormone optimization and hormonal correction for comprehensive anti-aging protocols.
The consultation works through the patient's goals, current health status, and any concurrent treatments to build the right protocol, not the most complex one.
Frequently Asked Questions
Are peptides FDA-approved?
The FDA classification of peptides varies. Semaglutide and tirzepatide are FDA-approved for diabetes and weight loss. Tesamorelin has FDA approval for HIV-associated lipodystrophy. Most other peptides (BPC-157, TB-500, CJC-1295, Ipamorelin, Semax, Selank, Epithalon) are prescribed off-label in the United States. They are not FDA-approved as drugs for the indications they are most commonly used for, but they are prescribed by licensed physicians within the scope of off-label prescribing practice.
How are peptides administered?
Most peptides at Rebuild Regen are administered via subcutaneous injection, which provides the most reliable and consistent absorption. The injections are shallow (into the fat layer below skin) and use small-gauge needles comparable to an insulin syringe. Most patients administer at home after in-office training. Some peptides (KPV, Semax, Selank) have oral or intranasal alternatives depending on the application.
Can peptides be combined with TRT or HRT?
Peptides and hormone therapy are frequently combined at Rebuild Regen. Growth hormone optimization peptides (CJC-1295, Ipamorelin) combined with TRT produce synergistic body composition results: testosterone addresses muscle protein synthesis and libido; GH peptides drive fat metabolism and tissue recovery. HRT combined with BPC-157 or TB-500 can support connective tissue health that declines with estrogen deficiency. Protocol design integrates all active treatments.
How long should I be on peptide therapy?
Protocol duration depends on the goal. Injury repair protocols typically run 8 to 16 weeks. Growth hormone optimization protocols are often used for 3 to 6 month cycles with breaks. Metabolic peptides (GLP-1 agonists) are typically ongoing while weight management goals are being addressed. Longevity peptides (Epithalon, Thymalin) are used episodically. The treating provider establishes duration and reassessment timing at consultation.
Do peptides cause side effects?
Peptide side effects are generally mild compared to pharmaceutical alternatives. Injection site reactions (redness, minor soreness) are common. GLP-1 agonists (semaglutide, tirzepatide) produce GI side effects (nausea, reduced appetite, occasional GI discomfort) that are managed by slow dose titration. Growth hormone peptides can cause mild water retention or tingling at high doses. The side effect profiles for each peptide are covered in detail at consultation.
Can I use multiple peptides at the same time?
Combining peptides from different categories is common and clinically appropriate when the goals support it. The key consideration is that combinations are designed by the treating provider based on the patient's full clinical picture, not self-assembled from internet research. Interactions between peptides are generally minimal due to the specificity of their receptor targeting, but protocol design ensures the combination is logical, monitored, and adjusted based on response.
When Peptide Therapy Is Not Indicated
Peptide therapy is not appropriate in all circumstances. The following contexts represent situations where peptides are contraindicated or require specific precautions:
Active cancer: Growth-promoting peptides (GHRH analogs, IGF-1-stimulating peptides, repair peptides with angiogenic properties) carry theoretical risk of stimulating tumor growth in patients with active malignancy. Oncology clearance is required before any growth-stimulating peptide protocol is initiated in patients with cancer history.
Uncontrolled diabetes: GLP-1 agonists (semaglutide, tirzepatide) are appropriate for patients with T2D who are already under some metabolic management. Initiating GLP-1 therapy in patients with severely uncontrolled diabetes requires coordination with the patient's primary or endocrinology provider.
Peptides as a substitute for lifestyle intervention: Peptide therapy produces meaningful clinical results, but it is not a replacement for the fundamental lifestyle inputs that support health. Patients who present expecting peptides to substitute for diet, sleep, and exercise will see inferior results and may develop unrealistic expectations. The consultation addresses lifestyle factors as part of the protocol design.
Self-prescribing without clinical oversight: The peptide marketplace includes research compounds sold online without clinical involvement. These products vary in purity, concentration accuracy, and sterility. Peptide therapy at Rebuild Regen uses pharmacy-grade compounds under clinical prescription. Patients using self-sourced research peptides are encouraged to discuss their full protocol honestly at consultation to avoid interactions and ensure safety.
Schedule a consultation: (954) 953-4208 | Rebuild Regen Medical Clinic, 3320 N Federal Hwy #101, Lighthouse Point, FL 33064.
Ready to Start Your Recovery?
Schedule a consultation with Rebuild Regen Medical Clinic in Lighthouse Point, FL.